VCYT logo

Veracyte, Inc. Stock Price

NasdaqGM:VCYT Community·US$2.7b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 16 Fair Values set on narratives written by author

VCYT Share Price Performance

US$34.80
0.87 (2.56%)
22.7% undervalued intrinsic discount
US$45.00
Fair Value
US$34.80
0.87 (2.56%)
22.7% undervalued intrinsic discount
US$45.00
Fair Value
Price US$34.80
AnalystHighTarget US$45.00
AnalystConsensusTarget US$40.07
AnalystLowTarget US$28.40

VCYT Community Narratives

AnalystHighTarget·
Fair Value US$45 22.7% undervalued intrinsic discount

Precision Medicine Growth Will Create New Global Opportunities

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AnalystConsensusTarget·
Fair Value US$39.75 12.5% undervalued intrinsic discount

Advanced Genomic And Cancer Diagnostics Will Expand Global Health Markets

0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
AnalystLowTarget·
Fair Value US$28.4 22.5% overvalued intrinsic discount

Restrictive US Policies And Commoditized AI Will Erode Margins

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

Recent VCYT News & Updates

Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking After Shares Rocket 27%

Aug 30
Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking After Shares Rocket 27%

Veracyte, Inc.'s (NASDAQ:VCYT) Shares Lagging The Industry But So Is The Business

Jun 15
Veracyte, Inc.'s (NASDAQ:VCYT) Shares Lagging The Industry But So Is The Business

Veracyte, Inc. Key Details

US$479.1m

Revenue

US$141.1m

Cost of Revenue

US$338.0m

Gross Profit

US$311.7m

Other Expenses

US$26.3m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
0.33
Gross Margin
70.55%
Net Profit Margin
5.50%
Debt/Equity Ratio
0%

Veracyte, Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Flawless balance sheet with moderate growth potential.

1 Risk
3 Rewards

About VCYT

Founded
2006
Employees
824
CEO
Marc Stapley
WebsiteView website
www.veracyte.com

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It is also developing the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

U.S. Market Performance

  • 7 Days: -2.7%
  • 3 Months: 5.1%
  • 1 Year: 13.4%
  • Year to Date: 11.7%
Over the last 7 days, the market has dropped 2.7%, driven by a loss of 2.5% in the Information Technology sector. In the last year, the market is actually up 13%. Earnings are forecast to grow by 15% annually. Market details ›